Drug Profile


Alternative Names: TAT4 gel

Latest Information Update: 25 Apr 2016

Price : $50

At a glance

  • Originator Topokine Therapeutics
  • Developer Allergan
  • Class Skin disorder therapies
  • Mechanism of Action Adipocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Facial-wrinkles
  • Phase I Lipodystrophy

Most Recent Events

  • 21 Apr 2016 Topokine Therapeutics has been acquired and merged into Allergan
  • 02 Jan 2016 Phase-II clinical trials in Facial wrinkles in USA (Topical) (NCT02607670)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top